Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Detecting meaningful change using the North Star Ambulatory Assessment in Duchenne muscular dystrophy.

Mayhew AG, Cano SJ, Scott E, Eagle M, Bushby K, Manzur A, Muntoni F; North Star Clinical Network for Neuromuscular Disease..

Dev Med Child Neurol. 2013 Nov;55(11):1046-52. doi: 10.1111/dmcn.12220. Epub 2013 Aug 5.

2.

Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.

Mayhew A, Cano S, Scott E, Eagle M, Bushby K, Muntoni F; North Star Clinical Network for Paediatric Neuromuscular Disease..

Dev Med Child Neurol. 2011 Jun;53(6):535-42. doi: 10.1111/j.1469-8749.2011.03939.x. Epub 2011 Mar 17.

3.

Functional changes in Duchenne muscular dystrophy: a 12-month longitudinal cohort study.

Mazzone E, Vasco G, Sormani MP, Torrente Y, Berardinelli A, Messina S, D'Amico A, Doglio L, Politano L, Cavallaro F, Frosini S, Bello L, Bonfiglio S, Zucchini E, De Sanctis R, Scutifero M, Bianco F, Rossi F, Motta MC, Sacco A, Donati MA, Mongini T, Pini A, Battini R, Pegoraro E, Pane M, Gasperini S, Previtali S, Napolitano S, Martinelli D, Bruno C, Vita G, Comi G, Bertini E, Mercuri E.

Neurology. 2011 Jul 19;77(3):250-6. doi: 10.1212/WNL.0b013e318225ab2e. Epub 2011 Jul 6.

PMID:
21734183
4.

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.

Ricotti V, Ridout DA, Pane M, Main M, Mayhew A, Mercuri E, Manzur AY, Muntoni F; UK NorthStar Clinical Network..

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):149-55. doi: 10.1136/jnnp-2014-309405. Epub 2015 Mar 2.

5.

Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.

Connolly AM, Florence JM, Cradock MM, Malkus EC, Schierbecker JR, Siener CA, Wulf CO, Anand P, Golumbek PT, Zaidman CM, Philip Miller J, Lowes LP, Alfano LN, Viollet-Callendret L, Flanigan KM, Mendell JR, McDonald CM, Goude E, Johnson L, Nicorici A, Karachunski PI, Day JW, Dalton JC, Farber JM, Buser KK, Darras BT, Kang PB, Riley SO, Shriber E, Parad R, Bushby K, Eagle M; MDA DMD Clinical Research Network..

Neuromuscul Disord. 2013 Jul;23(7):529-39. doi: 10.1016/j.nmd.2013.04.005. Epub 2013 May 28.

6.

Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.

Bello L, Piva L, Barp A, Taglia A, Picillo E, Vasco G, Pane M, Previtali SC, Torrente Y, Gazzerro E, Motta MC, Grieco GS, Napolitano S, Magri F, D'Amico A, Astrea G, Messina S, Sframeli M, Vita GL, Boffi P, Mongini T, Ferlini A, Gualandi F, Soraru' G, Ermani M, Vita G, Battini R, Bertini E, Comi GP, Berardinelli A, Minetti C, Bruno C, Mercuri E, Politano L, Angelini C, Hoffman EP, Pegoraro E.

Neurology. 2012 Jul 10;79(2):159-62. doi: 10.1212/WNL.0b013e31825f04ea. Epub 2012 Jun 27.

7.

24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy.

Mazzone ES, Pane M, Sormani MP, Scalise R, Berardinelli A, Messina S, Torrente Y, D'Amico A, Doglio L, Viggiano E, D'Ambrosio P, Cavallaro F, Frosini S, Bello L, Bonfiglio S, De Sanctis R, Rolle E, Bianco F, Magri F, Rossi F, Vasco G, Vita G, Motta MC, Donati MA, Sacchini M, Mongini T, Pini A, Battini R, Pegoraro E, Previtali S, Napolitano S, Bruno C, Politano L, Comi GP, Bertini E, Mercuri E.

PLoS One. 2013;8(1):e52512. doi: 10.1371/journal.pone.0052512. Epub 2013 Jan 11. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/cbe611fe-cda9-4d98-9574-0ac18e109daa.

8.

Corticosteroids for the treatment of Duchenne muscular dystrophy.

Matthews E, Brassington R, Kuntzer T, Jichi F, Manzur AY.

Cochrane Database Syst Rev. 2016 May 5;(5):CD003725. doi: 10.1002/14651858.CD003725.pub4. Review.

PMID:
27149418
9.

Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.

Mayhew JE, Florence JM, Mayhew TP, Henricson EK, Leshner RT, McCarter RJ, Escolar DM.

Muscle Nerve. 2007 Jan;35(1):36-42.

PMID:
16969838
10.

Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.

Goemans N, van den Hauwe M, Wilson R, van Impe A, Klingels K, Buyse G.

Neuromuscul Disord. 2013 Aug;23(8):618-23. doi: 10.1016/j.nmd.2013.05.006. Epub 2013 Jun 13.

PMID:
23770101
11.

Verbal and memory skills in males with Duchenne muscular dystrophy.

Hinton VJ, Fee RJ, Goldstein EM, De Vivo DC.

Dev Med Child Neurol. 2007 Feb;49(2):123-8.

12.

Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures.

Lerario A, Bonfiglio S, Sormani M, Tettamanti A, Marktel S, Napolitano S, Previtali S, Scarlato M, Natali-Sora M, Mercuri E, Bresolin N, Mongini T, Comi G, Gatti R, Ciceri F, Cossu G, Torrente Y.

BMC Neurol. 2012 Sep 13;12:91. doi: 10.1186/1471-2377-12-91.

13.

Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophy.

Connolly AM, Malkus EC, Mendell JR, Flanigan KM, Miller JP, Schierbecker JR, Siener CA, Golumbek PT, Zaidman CM, Mcdonald CM, Johnson L, Nicorici A, Karachunski PI, Day JW, Kelecic JM, Lowes LP, Alfano LN, Darras BT, Kang PB, Quigley J, Pasternak AE, Florence JM; MDA DMD Clinical Research Network..

Muscle Nerve. 2015 Apr;51(4):522-32. doi: 10.1002/mus.24346. Epub 2015 Feb 11.

14.

Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.

Alman BA, Raza SN, Biggar WD.

J Bone Joint Surg Am. 2004 Mar;86-A(3):519-24. Erratum in: J Bone Joint Surg Am. 2016 Jul 20;98(14):e62.

PMID:
14996877
15.

Suitability of North Star Ambulatory Assessment in young boys with Duchenne muscular dystrophy.

De Sanctis R, Pane M, Sivo S, Ricotti V, Baranello G, Frosini S, Mazzone E, Bianco F, Fanelli L, Main M, Corlatti A, D'Amico A, Colia G, Scalise R, Palermo C, Alfonsi C, Tritto G, Romeo DM, Graziano A, Battini R, Morandi L, Bertini E, Muntoni F, Mercuri E.

Neuromuscul Disord. 2015 Jan;25(1):14-8. doi: 10.1016/j.nmd.2014.09.015. Epub 2014 Oct 6.

PMID:
25454732
16.

Electrical impedance myography in Duchenne muscular dystrophy and healthy controls: A multicenter study of reliability and validity.

Zaidman CM, Wang LL, Connolly AM, Florence J, Wong BL, Parsons JA, Apkon S, Goyal N, Williams E, Escolar D, Rutkove SB, Bohorquez JL; DART-EIM Clinical Evaluators Consortium..

Muscle Nerve. 2015 Oct;52(4):592-7. doi: 10.1002/mus.24611. Epub 2015 Jul 24.

PMID:
25702806
17.

Prednisolone in Duchenne muscular dystrophy.

Rahman MM, Hannan MA, Mondol BA, Bhoumick NB, Haque A.

Bangladesh Med Res Counc Bull. 2001 Apr;27(1):38-42.

PMID:
11692899
18.

Comparison of motor strength and function in patients with Duchenne muscular dystrophy with or without steroid therapy.

Parreira SL, Resende MB, Zanoteli E, Carvalho MS, Marie SK, Reed UC.

Arq Neuropsiquiatr. 2010 Oct;68(5):683-8.

19.

Development and psychometric analysis of the Duchenne muscular dystrophy Functional Ability Self-Assessment Tool (DMDSAT).

Landfeldt E, Mayhew A, Eagle M, Lindgren P, Bell CF, Guglieri M, Straub V, Lochm├╝ller H, Bushby K.

Neuromuscul Disord. 2015 Dec;25(12):937-44. doi: 10.1016/j.nmd.2015.09.012. Epub 2015 Sep 26. Erratum in: Neuromuscul Disord. 2016 Apr-May;26(4-5):329.

20.

Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Manzur AY, Kuntzer T, Pike M, Swan A.

Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003725. doi: 10.1002/14651858.CD003725.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD003725.

PMID:
18254031

Supplemental Content

Support Center